Kymera Therapeutics

Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors

Read more

Development and Performance of Pharmacodynamic Assays to Demonstrate Proof-of-Mechanism for IRAK4 Degraders in a Phase1 Study

Read more

The Phase 1 Healthy Volunteer Clinical Trial of KT-474

Read more

Expression & Characterization of Novel Tissue Selective E3 Ligases

Read more

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

Read more

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

Read more

MQAtlas Creates a Deep, Accurate and Global E3 Expression Atlas Enabling Targeted Protein Degradation Based Precision Medicine

Read more

Utilizing degraders to Modulate B & T Cell Targets for Autoimmune Diseases

Read more

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

Read more

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Read more